Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000815497 | SCV000955955 | uncertain significance | Brody myopathy | 2018-11-06 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with serine at codon 438 of the ATP2A1 protein (p.Gly438Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with ATP2A1-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003353053 | SCV004063593 | uncertain significance | Inborn genetic diseases | 2023-07-31 | criteria provided, single submitter | clinical testing | The c.1312G>A (p.G438S) alteration is located in exon 12 (coding exon 12) of the ATP2A1 gene. This alteration results from a G to A substitution at nucleotide position 1312, causing the glycine (G) at amino acid position 438 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |